SafeRide Health (SRH) is the new provider for all NEMT rides to doctor appointments and pharmacy visits.
Depending on your needs, rides may include wheelchair-lift-equipped vehicles, stretcher vans, minivans, or ambulatory vans. Please let SRH know what type of ride you need when scheduling.
SafeRide Health (SRH) es el nuevo proveedor de todos los servicios de transporte médico que no son de emergencia (NEMT, por sus siglas en inglés) hacia consultas médicas y farmacias.
Según tus necesidades, los servicios de transporte pueden incluir vehículos con elevador para sillas de ruedas, camionetas con camilla, minivans o camionetas ambulatorias. Por favor, informa a SRH qué tipo de transporte necesitas al programar tu traslado.
Providers should monitor the Texas Children’s Health Plan (TCHP) Provider Portal regularly for alerts and updates associated to the COVID-19 event. TCHP reserves the right to update and/or change this information without prior notice due to the evolving nature of the COVID-19 event.
Call to action: Effective, February 1,2023, the Texas Health and Human Services Commission (HHSC) will update the prior authorization criteria for Amvuttra (procedure code J0225).
Amvuttra (vutrisiran) is a transthyretin-directed small interfering RNA indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated (HATTR) amyloidosis in adults.
How this impacts providers: Members must meet the following criteria for approval for 12 months:
Initial Requests
Member is 18 years of age or older
Diagnosis of hereditary transthyretin (hATTR) amyloidosis (diagnosis code: 5.1), supported by
Transthyretin (TTR) mutation proven by genetic testing
Clinical signs and symptoms of the disease (e.g., peripheral/autonomic neuropathy, motor disability)
Member will not receive Amvuttra (vutrisiran) therapy in combination with other polyneuropathy hATTR amyloidosis therapies (e.g., inotersen, tafamidis meglumine or patisiran).
Member will receive vitamin A supplementation at the recommended daily allowance while on Amvuttra (vutrisiran) therapy.
Member has not had a liver transplant.
Renewal or Continuation Therapy
Member has previously received treatment with Amvuttra (vutrisiran) without an adverse reaction.
Member has a positive clinical response to Amvuttra (e.g., improved neurologic impairment, improved motor function, slowing of disease progression).
Next steps for providers: Providers should share this communication with their staff. Refer to the Outpatient Drug Services Handbook Chapter of the Texas Medicaid Provider Procedure Manual (TMPPM) for more details on the clinical policy and prior authorization requirements.
